$17.25
0.61% today
NYSE, Sep 04, 07:18 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
8 days ago
Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind. , Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners to sponsor Nutrition Secure Indianapolis, a fir...
Neutral
PRNewsWire
9 days ago
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acq...
Neutral
PRNewsWire
9 days ago
GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.
Neutral
Seeking Alpha
28 days ago
Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.
Positive
Seeking Alpha
28 days ago
I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive ou...
Positive
The Motley Fool
28 days ago
Elanco Animal Health (ELAN -1.76%), a global animal health company providing products and services for pets and livestock, reported its second quarter 2025 earnings on August 7, 2025. The most notable news was a strong revenue beat and solid performance in its innovation portfolio, especially from new pet and cattle products.
Neutral
PRNewsWire
28 days ago
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter  2025 Financial Results: Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growth Reported Net Income of $11 million, Adjusted Net Income of $131 million Adjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2%  Reported EPS of $0.02, Adjus...
Neutral
PRNewsWire
about one month ago
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the world Launch to begin immediately with product in market before the end of Q3 2025 GREENFIELD, Ind. , July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today